Soleo Health Archives - CDR – Chain Drug Review

Soleo Health named limited drug distribution partner by Mitsubishi Tanabe Pharma America

June 7, 2022 by Chain Drug Review Soleo Health Pharmacy

FRISCO, Texas — Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced Tuesday it was named one of only four limited distribution drug (LDD) specialty pharmacy partners to dispense nationwide RADICAVA ORS (edaravone) oral suspension, commercialized by Mitsubishi Tanabe Pharma America, Inc. (MTPA), which commercializes approved pharmaceutical products in North

Soleo Health receives accreditation as specialty pharmacy

January 31, 2022 by Chain Drug Review Soleo Health Leading Headlines, Pharmacy

FRISCO, Texas — Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced Monday it achieved accreditation through the Accreditation Commission for Health Care(ACHC) as a specialty pharmacy with distinction in rare disease and orphan drugs. The Company is one in only six nationally to earn this prestigious ACHC distinction. Accreditation

Soleo Health names Becky Rand VP of business development

June 22, 2021 by Chain Drug Review Becky Rand, Soleo Health Pharmacy

FRISCO, Texas — Soleo Health, an innovative leader and national provider of complex specialty pharmacy and infusion services, announced today the appointment of Becky Rand to the post of vice president business development, industry relations. In this capacity, Rand will be responsible for initiating and maintaining relationships with pharmaceutical manufacturers and biotechnology companies where Soleo’s care model

Soleo Health selected by Genentech to provide two limited distribution drugs

June 27, 2018 by Chain Drug Review Craig Vollmer, Genentech, Hemlibra, Ocrevus, Soleo Health Pharmacy, Supplier News

McKINNEY, Texas — Soleo Health, an innovative leader in specialty infusion services, announced the company has been selected by Genentech (member of the Roche Group), a world-leading biotechnology company with multiple products on the market and a strong development pipeline, to dispense two limited distribution drugs, Hemlibra and Ocrevus. Hemlibra (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from